The Latest Updates
on Our Companies

June 30, 2023 in Turret Capital Management

Baudax Bio Acquires TeraImmune, Inc.

TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the Strong Development team from Baudax Baudax Bio CEO Gerri Henwood…
Read More
April 23, 2023 in Sable Therapeutics

Sable Therapeutics Announces Licensing Agreement with Shanghai Liuqiang Medical Technology Co.

For Development and Commercial Rights to its Fat Reducing SBL-003/SBL-004 Microneedle Patch in Greater China. Sable Therapeutics, a portfolio company of Turret Capital Management, announces licensing agreement for Greater China NEW…
Read More
February 4, 2023 in Egret Therapeutics

Egret Therapeutics Receives FDA Clearance of IND Application for EGT 101 for Treatment of Delayed Cerebral Ischemia

Egret Therapeutics, a portfolio company of Turret Capital Management, announces FDA Clearance of its IND Application for EGT 101 NEW YORK, Feb. 4, 2023 /PRNewswire/ -- Egret Therapeutics, a clinical-stage biotechnology company…
Read More
January 3, 2023 in Egret Therapeutics

Egret Therapeutics Announces the Addition of Three New Members to its Scientific Advisory Board

Egret Therapeutics, a portfolio company of Turret Capital Management, Announces the Addition of Three New Members. NEW YORK, Jan. 3, 2023 /PRNewswire/ -- Egret Therapeutics, a clinical-stage company focused on the treatment…
Read More
February 15, 2022 in Egret Therapeutics

Egret Therapeutics completes oversubscribed pre-A financing round

NEW YORK, Feb. 15, 2022 /PRNewswire/ -- Egret Therapeutics, a clinical-stage biotherapeutics company focused on the treatment of neurological diseases, announced today the completion of its pre-A financing. The funding was led by…
Read More
January 26, 2021 in Koi Therapeutics, Turret Capital Management

Turret Capital Announces Dr. Mary Lake Polan To Join Board Of Directors Of Koi Therapeutics

NEW YORK, Jan. 15, 2021 /PRNewswire/ -- Turret Capital Management announced today that Dr. Mary Lake Polan has been appointed to the Board of Directors of its subsidiary company, Koi Therapeutics. Mary Lake Polan,…
Read More
January 26, 2021 in Turret Capital Management

Turret Capital announces a global in-licensing agreement with Genexine

NEW YORK, Jan. 19, 2021 /PRNewswire/ -- Turret Capital Management, a global investment and venture building firm focused on the healthcare industry, announced today that it has signed a Definitive License Agreement with…
Read More
June 29, 2020 in Turret Capital Management

Turret Capital Management and Or-Genix Therapeutics Establish Strategic Partnership

NEW YORK, June 29, 2020 /PRNewswire/ -- Turret Capital Management, a global venture building and investment firm focused on the healthcare industry, has signed a Definitive License Agreement with Or-Genix Therapeutics, Inc. Under the…
Read More
October 23, 2019 in Milu Labs

Milu Labs and Thermo Fisher Scientific Announce Collaboration MOU to Advance the expansion of “Women’s Health products” in the China market

NEW YORK, Oct. 23, 2019 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, and Milu Labs., whose mission is to become the leading diagnostic and analysis company focused on cutting edge…
Read More